Clinical Trial Update: Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating the HDL-C-raising mechanism of rosuvastatin (Crestor) by measuring steps of reverse cholesterol transport; the study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Metabolic Syndrome

Drugs mentioned

• CRESTOR (Rosuvastatin)

Snippet

Sponsor: AstraZeneca | Conditions: Metabolic Syndrome, Dyslipidemia | Phase 3 | Status: COMPLETED